Investigation of REcurrence Mechanisms to Adjuvant osimertINib in Radically Resected EGFR-mutated NSCLC Patients

NCT07363252 · clinicaltrials.gov ↗

RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

EGFR-mutated NSCLC

Interventions

DRUG: Osimertinib

Sponsor

Gruppo Oncologico Italiano di Ricerca Clinica